Trial · NCT00296335

Trial of Adjuvant Chemotherapy for Gastric Cancer

NCT00296335, Phase 3, Completed, Asan Medical Center; results first posted 2014-02-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of Adjuvant Chemotherapy for Gastric Cancer. Trials, record NCT00296335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00296335

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of Adjuvant Chemotherapy for Gastric Cancer
NCT number: NCT00296335
Status: Completed
Phases: Phase 3
Enrollment: 855 participants, actual
Lead sponsor: Asan Medical Center
Conditions: Stomach Cancer
Interventions: Mitomycin, doxifluridine and cisplatin, Mitomycin and doxifluridine
First posted: 2006-02-27
Last updated: 2014-02-27
Results first posted: 2014-02-27

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Relapse-free Survival Rate	3 years	Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery. Relapse was defined as any new tumor lesion.
Secondary	Overall Survival Rate	3 years	Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery.
Secondary	Number of Patients With Adverse Events	Up to 3 years	Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Relapse-free Survival Rate	3 years	Intention-to treat population	percentage of participants	NUMBER
SECONDARY	Overall Survival Rate	3 years		percentage of participants	NUMBER
SECONDARY	Number of Patients With Adverse Events	Up to 3 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Relapse-free Survival Rate	Mitomycin Plus Short-term Fluoropyrimidine		67.0	95% Confidence Interval 62.5 to 71.5	percentage of participants
Relapse-free Survival Rate	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati		64.9	95% Confidence Interval 60.4 to 69.4	percentage of participants
Overall Survival Rate	Mitomycin Plus Short-term Fluoropyrimidine		76.9	95% Confidence Interval 72.9 to 80.9	percentage of participants
Overall Survival Rate	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati		73.1	95% Confidence Interval 68.9 to 77.3	percentage of participants
Number of Patients With Adverse Events	Mitomycin Plus Short-term Fluoropyrimidine	Neutropenia	262		participants
Number of Patients With Adverse Events	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	Neutropenia	387		participants
Number of Patients With Adverse Events	Mitomycin Plus Short-term Fluoropyrimidine	Anemia	393		participants
Number of Patients With Adverse Events	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	Anemia	413		participants
Number of Patients With Adverse Events	Mitomycin Plus Short-term Fluoropyrimidine	Thrombocytopenia	101		participants
Number of Patients With Adverse Events	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	Thrombocytopenia	156		participants

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mitomycin and Doxifluridine	424
Overall Study	STARTED	Mitomycin, Doxifluridine and Cisplatin	431
Overall Study	COMPLETED	Mitomycin and Doxifluridine	394
Overall Study	COMPLETED	Mitomycin, Doxifluridine and Cisplatin	309
Overall Study	NOT COMPLETED	Mitomycin and Doxifluridine	30
Overall Study	NOT COMPLETED	Mitomycin, Doxifluridine and Cisplatin	122

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Neutropenia	Blood and lymphatic system disorders	Mitomycin Plus Short-term Fluoropyrimidine	262	422
other	Neutropenia	Blood and lymphatic system disorders	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	387	425
other	Anemia	Blood and lymphatic system disorders	Mitomycin Plus Short-term Fluoropyrimidine	393	422
other	Anemia	Blood and lymphatic system disorders	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	413	425
other	Thrombocytopenia	Blood and lymphatic system disorders	Mitomycin Plus Short-term Fluoropyrimidine	101	422
other	Thrombocytopenia	Blood and lymphatic system disorders	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	156	425
other	Hyperbilirubinemia	Hepatobiliary disorders	Mitomycin Plus Short-term Fluoropyrimidine	114	422
other	Hyperbilirubinemia	Hepatobiliary disorders	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	162	425
other	Fatigue	General disorders	Mitomycin Plus Short-term Fluoropyrimidine	343	422
other	Fatigue	General disorders	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	391	425

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Mitomycin Plus Short-term Fluoropyrimidine
Total, all-cause mortality	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati
Total, other adverse events	Mitomycin Plus Short-term Fluoropyrimidine	393	422
Total, other adverse events	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	413	425
Total, serious adverse events	Mitomycin Plus Short-term Fluoropyrimidine	3	422
Total, serious adverse events	Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati	5	425

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Mitomycin Plus Short-term Fluoropyrimidine vs Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00296335

GET https://conductscience.org/api/trials/v1/NCT00296335/events?page=2

API reference For AI assistants